New Data from Boehringer Ingelheim HCV Portfolio to be Presented at AASLD
RIDGEFIELD, Conn., Oct. 3, 2011 /PRNewswire/ — Boehringer Ingelheim Pharmaceuticals, Inc. announced today that new data from its hepatitis C virus (HCV) portfolio will be presented in scientific sessions at The Liver MeetingÃ‚® 2011, the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place November 4 – November 8 in San Francisco, CA. The data will include results from a planned interim analysis of SOUND-C2, a Phase 2b study evaluating an interferon-free oral combination therapy of BI’s investigational compounds – the protease inhibitor BI 201335 and the polymerase inhibitor BI 207127 – with and without ribavirin.
In addition, other data are being presented from BI’s HCV portfolio that underscore the company’s focus on real-world challenges faced by HCV patients, including traditionally difficult-to-treat populations.
Late breaking poster presentation
- Virologic response to an interferon-free regimen of BI 201335 and BI 207127, with and without ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: Week 12 interim results of the SOUND-C2 study
(Poster LB-15. Zeuzem, et al. November 7, 8:00 a.m. – 5:30 p.m. PT)
- SILEN-C3: Treatment for 12 or 24 weeks with BI 201335 combined with peginterferon alfa-2a and ribavirin (P/R) in treatment-naive patients with chronic genotype-1 HCV infection
(Abstract 39. D. Dieterich, et al. November 6, 4:15 p.m. – 4:30 p.m. PT)
- Treatment with the second generation HCV protease inhibitor BI 201335 results in high and consistent SVR rates – results from SILEN-C1 in treatment-naive patients across different baseline factors
(Abstract 226. M.S. Sulkowski, et al. November 8, 8:45 a.m. – 9:00 a.m. PT)
- High sustained virologic response following interferon-free treatment of chronic HCV GT1 infection for 4 weeks with HCV protease inhibitor BI 201335, polymerase inhibitor BI 207127 and ribavirin, followed by BI 201335 and PegIFN/ribavirin – the SOUND-C1 study
(Abstract 249. S. Zeuzem, et al. November 8, 11:15 a.m. – 11:30 a.m. PT)
- Characterization of HCV NS3 variants that emerged during virologic breakthrough and relapse from BI 201335 phase 2 SILEN-C1 study
(Poster 1339. G. Kukolj, et al. November 7, 8:00 a.m. – 5:30 p.m. PT)
Boehringer Ingelheim is continuing its long heritage in virology and is dedicated to developing new medicines for HCV patients. BI 201335 and BI 207127 are being investigated with the goal of improving cure rates for more HCV patients, including those traditionally difficult to treat.
The abstracts can be accessed through the AASLD website, www.aasld.org.
Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.
In 2010, Boehringer Ingelheim posted net sales of about 12.6 billion euro while spending almost 24% of net sales in its largest business segment, Prescription Medicines, on research and development.
SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.